报告期内，公司主要因集采政策陆续执行导致销售价格下降、自产试剂产品增值税税率调整为13%和产 品销量结构的变化等原因导致收入下降;财务收益的下降和汇兑损益减少等原因导致经营业绩亏损。公 司积极应对市场竞争情况，加强产品研发，挖掘潜力，优化降本增效举措，不断提高产品的市场竞争 力，提升公司经营能力。公司成本费用管控措施落地见效，资产减值损失同比减少，2025年同比去年经 营情况实现减亏。 之江生物(688317.SH)发布2025年度业绩快报，报告期内，公司实现营业总收入12,491.36万元，比上年 同期下降30.08%;实现归属于母公司所有者的净利润-3,430.38万元，比上年同期减少亏损9,315.83万元。 ...

智通财经APP讯，之江生物(688317.SH)发布2025年度业绩快报，报告期内，公司实现营业总收入 12,491.36万元，比上年同期下降30.08%;实现归属于母公司所有者的净利润-3,430.38万元，比上年同期 减少亏损9,315.83万元。 报告期内，公司主要因集采政策陆续执行导致销售价格下降、自产试剂产品增值税税率调整为13%和产 品销量结构的变化等原因导致收入下降;财务收益的下降和汇兑损益减少等原因导致经营业绩亏损。公 司积极应对市场竞争情况，加强产品研发，挖掘潜力，优化降本增效举措，不断提高产品的市场竞争 力，提升公司经营能力。公司成本费用管控措施落地见效，资产减值损失同比减少，2025年同比去年经 营情况实现减亏。 ...

格隆汇2月27日丨之江生物(688317.SH)公布2025年年度业绩快报，报告期内，公司实现营业总收入 12,491.36万元，比上年同期下降30.08%；实现归属于母公司所有者的净利润-3,430.38万元，比上年同期 减少亏损9,315.83万元；实现归属于母公司所有者的扣除非经常性损益的净利润-4,771.48万元，比上年 同期减少亏损8,055.65万元。 报告期内，公司主要因集采政策陆续执行导致销售价格下降、自产试剂产品增值税税率调整为13%和产 品销量结构的变化等原因导致收入下降；财务收益的下降和汇兑损益减少等原因导致经营业绩亏损。公 司积极应对市场竞争情况，加强产品研发，挖掘潜力，优化降本增效举措，不断提高产品的市场竞争 力，提升公司经营能力。公司成本费用管控措施落地见效，资产减值损失同比减少，2025年同比去年经 营情况实现减亏。 ...

之江生物公告称，2025年度公司实现营业总收入12,491.36万元，同比下降30.08%；归属于母公司所有 者的净利润-3,430.38万元，同比减少亏损9,315.83万元。报告期末，公司总资产376,367.96万元，较期初 减少0.69%；归属于母公司的所有者权益334,879.63万元，较期初减少7.92%。收入下降主要因集采政 策、税率调整和产品销量结构变化；经营业绩亏损因财务收益下降和汇兑损益减少，但同比实现减亏。 ...

内容概要：我国高血压、心力衰竭、心律失常等心血管疾病的患病人群总量庞大，且随着人口老龄化加 剧、居民生活方式改变，这类慢性疾病的发病率仍在稳步上升，琥珀酸美托洛尔缓释片凭借长效平稳的 药效、优异的用药依从性，成为心血管疾病的一线与基础治疗药物，临床不可替代性突出，拥有天然的 刚性需求，据药通社数据显示，2022年我国琥珀酸美托洛尔缓释片销售额达32.3亿元，同比增长4.7%， 但近几年，受集采降价影响，我国琥珀酸美托洛尔缓释片销售额有所下滑，2024年我国琥珀酸美托洛尔 缓释片销售额降至23.9亿元，同比减少4.6%，2025年上半年我国琥珀酸美托洛尔缓释片销售额共计完成 13.7亿元。 上市企业：东阳光（600673）、华海药（600521） 相关企业：阿斯利康制药有限公司、合肥合源药业有限公司、南通联亚药业股份有限公司、华益泰康药 业股份有限公司、浙江普洛康裕制药有限公司、佛山德芮可制药有限公司、广西厚德药业有限公司、宜 昌人福药业有限责任公司、重庆药友制药有限责任公司 关键词：琥珀酸美托洛尔缓释片行业相关政策汇总、琥珀酸美托洛尔缓释片产业链图谱、琥珀酸美托洛 尔缓释片销售额、琥珀酸美托洛尔缓释片竞争格局 ...

Regulatory Situation - In January 2026, the company was fined a total of 3.125 million yuan by the Shandong Provincial Drug Administration for producing and selling substandard sodium bicarbonate injection, following a penalty decision made in November 2025 [2] Performance and Operating Conditions - For the first three quarters of 2025, the company reported revenue of 2.584 billion yuan, a year-on-year decrease of 13.94%, and a net profit attributable to shareholders of 382 million yuan, down 4.05% year-on-year. In the third quarter alone, net profit increased by 19.61% year-on-year, although the non-recurring net profit declined, indicating fluctuations in profit quality. The company's debt ratio stands at 18.72%, with a gross margin of 55.08% [3] Product Development Progress - The company has multiple innovative drug pipelines in clinical phase II, including WX-081 tablets and WX390 tablets. Additionally, a flu treatment drug, WXSH0208 tablets, has received approval for clinical trials. The subsidiary, Chenshin Fudu Pharmaceutical, has expanded its coverage for oral liquid products under medical insurance, although specific launch dates have not been announced [4] Capital Movements - As of February 6, 2026, the company experienced a weekly net inflow of 12.4296 million yuan in principal funds, with significant daily fluctuations. On February 6, the net inflow reached 20.6828 million yuan. The stock price has been fluctuating around the 17-18 yuan range, with technical indicators showing dispersed holdings and market sentiment influenced by the overall industry [5] Future Development - The company's subsidiary, Shandong Chenshin Fudu Pharmaceutical, has plans to list on the Beijing Stock Exchange, which were approved in 2024, but further progress will depend on official announcements. The pharmaceutical sector is affected by centralized procurement policies and trends in innovative drug development, requiring the company to balance regulatory risks with growth opportunities [6]

Core Viewpoint - The company is experiencing significant financial challenges, with declining profits and a weak stock performance, influenced by industry policies and market conditions [2][3][8]. Financial Performance - In the first three quarters of 2025, the company's net profit attributable to shareholders was 112 million yuan, a year-on-year decrease of 45.69% [2]. - The net profit for the third quarter alone was 39.3 million yuan, down 44.51% year-on-year [2]. - The gross margin has further declined to 8.02%, with a net margin of only 1.41%, indicating pressure on profit quality [3]. Market Activity - On February 13, the stock closed at 10.69 yuan, down 1.02%, and hit a 60-day low, with a trading volume of 69.91 million yuan and a turnover rate of 1.12% [1]. - There was a net outflow of 3.72 million yuan from main funds, continuing a trend of net outflows over recent days [4]. - The overall pharmaceutical commercial sector saw a net outflow of 184 million yuan, indicating a weak funding environment that exacerbates selling pressure on individual stocks [5]. Valuation and Technical Indicators - The stock price has fallen below the 60-day moving average, with the MACD histogram turning negative at -0.18, and the KDJ indicator showing an oversold signal with the J line at -4.44 [6]. - The lower support level of the Bollinger Band has shifted to 10.37 yuan, and breaching this level could trigger further technical selling pressure [7]. Industry Environment - The pharmaceutical commercial sector declined by 0.89% due to common industry factors such as deepening centralized procurement and extended medical insurance reimbursement cycles [8]. - Investor sentiment has been cautious ahead of the Spring Festival, leading to reduced positions due to concerns over market volatility during the holiday [8]. Financial Risks - The accounts receivable reached 4.079 billion yuan, accounting for 58.19% of total assets, highlighting significant pressure on cash flow [10]. - Despite efforts to expand the DTP pharmacy business, which saw a revenue increase of 22.81%, it is unlikely to offset the decline in wholesale business in the short term [10]. Future Outlook - The recent stock price breakdown is attributed to weak performance, risk aversion in funding, and technical breakdowns [11]. - Short-term focus should be on the effectiveness of the 10.37 yuan support level and whether first-quarter performance can improve [11]. - While industry policies may drive transformation, the market is more concerned with accounts receivable management and the substantive recovery of profitability [11].

21世纪经济报道记者唐唯珂报道 深耕胰岛素领域十年后，华润系选择与天麦生物"分道扬镳"。 2月9日，华润医药发布公告称，其全资附属公司华润医药投资拟通过上海联合产权交易所公开挂牌，转 让所持合肥天麦生物科技发展有限公司(下称"天麦生物")约17.87%股权，挂牌底价约14.2亿元。以此计 算，该笔股权对应天麦生物整体估值约80亿元。 据华润医药集团公告，若确定意向受让方，双方将订立相关协议；若期满未果，则本次公开挂牌将自动 失效并终止。根据上海联合产权交易所网站，信息披露日期截止到3月13日。这意味着，留给潜在意向 方的时间已经不多了。 尽管此次华润医药投资并未清仓所有股份，但华润系退意已决。目前，华润医药投资作为天麦生物第一 大股东，手握20%股权。一旦这笔交易落槌，其持股将降至5.88%，彻底告别大股东之位，其附属公司 (持有3.75%股权)将彻底退出。 华南某券商从业者向21世纪经济报道记者指出，从2016年战略入股携手开拓胰岛素市场，到2026年挂牌 出让大部分股权，这场持续十年的合作落幕，既折射出华润系聚焦主业的资产整合逻辑，也与天麦生物 核心研发管线口服胰岛素遇挫、行业竞争格局变化密切相关。 口服 ...

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase exceeding 15% relative to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 items across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 93.28 million yuan, 63.57 million yuan, 67.13 million yuan, and 77.75 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. - The company's gross margin is expected to be 62.45%, 57.80%, 58.05%, and 58.90% from 2022 to 2025 [50]. Business Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium-sized Enterprises" [3][28]. Competitive Position - The company ranks third among domestic manufacturers of spinal vertebral body shaping systems and sixth among spinal implant manufacturers [3][28]. - Aide Technology has a well-established national sales network and a strong communication mechanism with hospitals and orthopedic surgeons, enhancing product recognition and market penetration [5][35]. Investment Analysis - The company is positioned to benefit from the ongoing trend of centralized procurement in the industry, which is expected to normalize pricing and enhance market opportunities [4][36]. - The company’s revenue from non-procurement products is growing, helping to offset declines in procurement product revenues [47]. Use of Proceeds - The company plans to use the proceeds from its public offering for expanding orthopedic consumables production, building a research center, and enhancing its marketing network [53][54].

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on eye care, cardiovascular, respiratory, and digestive diseases. Revenue for the first three quarters of 2025 was 1.89 billion CNY, a decrease of 1.0% year-on-year, while net profit attributable to the parent company was 250 million CNY, an increase of 68.4% [13][9]. - The core TCM product, Compound Thrombus-Relieving Capsule, is a unique original formulation with a leading market share in the domestic ophthalmic TCM sector. The impact of centralized procurement is gradually being digested, and sales are expected to stabilize [9][10]. 2. Innovative Product Data and Growth Potential - The company has multiple innovative products entering commercialization or late-stage clinical trials. The PB2-targeted RNA polymerase inhibitor, Anladiwei Tablets, was approved in May 2025 for treating adult uncomplicated influenza, showing competitive advantages over Oseltamivir [9][27]. - The GLP-1/GIP dual-target drug RAY1225 for obesity and diabetes has entered Phase III clinical trials, with promising results indicating better weight loss efficacy compared to existing treatments [27][29]. 3. Financial Forecast and Investment Recommendations - The company’s revenue is projected to recover, with expected revenues of 2.803 billion, 3.126 billion, and 3.447 billion CNY for 2025, 2026, and 2027 respectively, reflecting growth rates of 13.6%, 11.5%, and 10.3% [5]. - The report emphasizes the importance of innovation and performance assessment, with an employee stock ownership plan launched in 2024 to incentivize core personnel [23][24].